Stock Alert: Esperion Therapeutics (ESPR)

(RTTNews) - Esperion Therapeutics Inc. (ESPR) has been hitting new highs and is already up nearly 24 percent so far this year.

Esperion is a pharmaceutical company developing non-statin, once-daily, oral therapies to lower elevated low-density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies.

The Company has two upcoming regulatory catalysts to watch out for this month.

The FDA decision on the Company's Bempedoic acid, proposed for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C), is expected by February 21, 2020.

A combination tablet of Bempedoic acid/Ezetimibe is also under FDA review, with a decision expected by February 26, 2020.

The above two investigational drugs are also under review by the European Medicines Agency, with a decision anticipated in April.

ESPR has traded in a range of $33.13 to $76.98 in the last 1 year. The stock closed Thursday's trading at $73.84, up 5.32%. In after-hours, the stock was up another 1.23% at $74.75.